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a  b  s  t  r  a  c  t
Cell  cycle  deregulation  is  common  in human  hepatocellular  carcinoma  (HCC).  To ensure
proper  cell  cycle  controlling,  cyclin/cyclin-dependent  kinases  (CDK)  complexes  are  tightly
regulated  by  CDK  inhibitors  (CKIs)  in normal  cells.  However,  insufﬁcient  cyclin-dependent
kinase  inhibitor  1B  (CDKN1B,  also  known  as  p27Kip1) and  CDKN1C  (p57Kip2)  proteins  are
characteristics  of high-risk  HCC.  In  two  HCC-derived  cell  lines  with  distinct  genetic  back-
grounds,  we  identiﬁed  a small  natural  compound,  goniothalamin  (GTN),  serving  as an
inducer  of  CKIs.  In TP53-mutated  (Y220C)  and  retinoblastoma  1 (RB1)-positive  Huh-7  cells,
GTN stabilized  CDKN1B  protein  levels  by  targeting  the degradation  of its  speciﬁc  E3  ubiqui-
tin ligase  (S-phase  kinase-associated  protein  2).  Alternatively,  in  TP53-  and  RB1-negative
Hep-3B  cells,  GTN  increased  CDKN1C  transcription  and  its subsequent  translation  by  acting
as a histone  deacetylase  inhibitor.  In  both  cell lines,  GTN  induced  G0/G1 cell  cycle  arrest,
delayed  S phase  entry  of  cells  and  inhibited  anchorage-independent  cell  growth  which
might be  attributed  to the upregulation  of  CKIs  and  downregulation  of  several  positive
cell cycle  regulators,  including  CDC28  protein  kinase  regulator  subunit  1B,  cyclin  E1 and
D1, cyclin-dependent  kinase  2 (CDK2),  CDK4,  CDK6,  E2F  transcription  factor  1  and/or  tran-
scription  factor  Dp-1. The
induces  CKIs  through  pos
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. Introduction
Hepatocellular carcinoma (HCC) is the most com-
on  primary malignant neoplasm of the liver worldwide,
ccounting approximately 6% of all human cancers annu-
lly (reviewed in [39]). Although substantial advances have
een made in chemotherapy regimens for HCC, the efﬁ-
acy of drugs is often hampered by a range of adverse
ide effects (reviewed in [53]). Clinical and genetic hetero-
eneity observed in HCC patients further complicates the
se of general therapies (reviewed in [19]). Accordingly,
here remains a critical need for both continued molecular
haracterization and aggressive drug development in HCC
reviewed in [16]).
Cell cycle deregulation is common in human HCC. Many
tudies have highlighted that G1 phase-associated cell cycle
egulators might be closely implicated in the early steps of
arcinogenesis (reviewed in [10]). Two major cyclin/cyclin-
ependent kinase (CDK) complexes are involved in the
rogression of G1: cyclin D/CDK4 or CDK6 complex for
arly G1 phase and cyclin E/CDK2 complex for late G1 to S
hase. These cyclin/CDK complexes are required for hyper-
hosphorylation of the retinoblastoma 1 (RB1), leading to
he transcription of genes implicated in S phase progres-
ion. Conversely, G1 phase-related cyclin-CDK complexes
re negatively regulated by a series of CDK inhibitors (CKIs)
n normal cells. Diminished expression of cyclin-dependent
inase inhibitor 1B (CDKN1B, also known as p27) [20,32]
nd cyclin-dependent kinase inhibitor 1C (CDKN1C, p57)
15,37] predict poor prognosis in the hepatocellular car-
inoma. It is generally believed that CDKN1B is degraded
ia the ubiquitin-proteasome system (UPS) in cancer cells
34,41], while CDKN1C is inactivated via either UPS or epi-
enetic modiﬁcations [6].
Studies performed over the past two decades by us and
ther researches have shown that, goniothalamin (GTN),
 plant bioactive styryllactones mainly isolated from the
enus Goniothalamus,  is cytotoxic to a variety of tumor cell
ines including those from the breast, blood, ovary, cer-
ical, lung, kidney, prostate, hepatoblast, colon and liver
1–3,9,11,22,23,26,28,45]. Besides, GTN is more cytotoxic
o cancer than to normal cells [52].
Numerous studies also showed that GTN induced apo-
tosis via caspase-dependent (CASP2, -3, -7, -8 and/or -9)
athways in different carcinoma-derived cells including
ervix (HeLa) [4], promyelocytic leukemia (HL-60), histi-
cytic lymphoma (U937) [21], leukemia (Jurkat T) [22,23],
epatocellular carcinoma (Hep-G2) [1] as well as coronary
rtery smooth muscle cells [8]. Undeniably, DNA dam-
ge response of mammalian cells usually involves cell
ycle arrest and DNA repair or, if unsuccessful, cell death
reviewed in [40]). We  earlier identiﬁed that GTN induces
he formation of reactive oxygen species (ROS)/DNA
ouble-strand breaks (DNA damage), transactivation of
umor protein p53 (TP53) and/or pophorbol-12-myristate-
3-acetate-induced protein 1 (PMAIP1) gene, translocation
f TP53 and/or PMAIP1 protein to mitochondria, release
f cytochrome c from mitochondria, cleavages of caspase
 (CASP8), -9, -3, poly (ADP-ribose) polymerase 1, and
nduction of apoptosis, sequentially, in both TP53-positive
nd -negative HCC cell lines [26]. However, prior to theorts 2 (2015) 322–332 323
occurrence of apoptosis, how GTN dysregulated cell cycle
progression remained unclear. We  herein identiﬁed that
GTN induced G0/G1 cell-cycle arrest by upregulation of two
CKIs, CDKN1B and CDKN1C, in two distinct HCC-derived
cell lines, the underlying regulatory mechanisms were also
studied.
2. Materials and methods
2.1. Cell culture
Two HCC-derived cell lines, Huh-7 and Hep-3B, were
maintained in a humidiﬁed incubator with 5% CO2 atmo-
sphere at 37 ◦C in Dulbecco’s Modiﬁed Eagle’s Medium and
Medium Essential Medium (CORNING), respectively, sup-
plemented with 10% fetal bovine serum, 1% l-glutamine
(2 mM),  1% nonessential amino acids, 1 mM sodium pyru-
vate, 50 IU/mL penicillin and 50 g/mL streptomycin
(Sigma–Aldrich). These two cell lines were known to have
distinct genetic backgrounds. The Huh-7 is characterized
by expression of mutated TP53 (Y220C), cyclin-dependent
kinase inhibitor 1A (CDKN1A, i.e., p21Cip1), RB1 proteins,
and the absence of hepatitis B virus surface antigen,
while pertinent features of these markers are complete
opposite in Hep-3B cells, including the absent of TP53
gene [11,44].
2.2. Chemicals
GTN was prepared as our previous study [27] dissolved
in dimethyl sulfoxide (DMSO). The maximum amount of
DMSO in culture medium was  1/1000. All chemicals unless
otherwise stated were purchased from Sigma–Aldrich.
N-(1H-Benzotriazol-1-yl)-2,4-dichlorobenzamide (ITSA1,
CAS 200626-61-5), an histone deacetylase (HDAC) activa-
tor by suppression of trichostatin A (TSA) [25] was  obtained
from Santa Cruz Biotechnology. Cycloheximide (CHX),
MG132 (a proteasome inhibitor), 5-Aza-2′-deoxycytidine
(5-Aza, an epigenetic modiﬁer inhibits DNA methyl-
transferase), TSA and ITSA1 were dissolved in DMSO.
All working solutions were freshly prepared from
stocks.
2.3. Flow cytometry
Literally 5 × 105 cells were treated with DMSO (con-
trol) or GTN (Huh-7: 20 M;  Hep-3B: 15 M)  for 24 h,
collected, washed with ice-cold PBS twice, ﬁxed with 80%
ethanol and stored at −20 ◦C. Before analysis, ﬁxed cells
were washed with ice-cold PBS for three times, treat-
ments with 200 g/mL RNase A (#78020Y, Affymetrix)
and 20 g/mL propidium iodide for 3 h. To analyze the
cell cycle distribution, a total of 10,000 events were
examined using a Coulter® Epics® XLTM Flow Cytome-
ter (Beckman Coulter) and the Modﬁt software (BD
Biosciences).2.4. Soft agar assay
CytoSelectTM 96-Well In Vitro Tumor Sensitiv-
ity Assay (soft agar colony formation, CBA-150, Cell
logy Rep324 Y.-T. Peng et al. / Toxico
Biolabs, Inc.) was used to analyze GTN-mediated alter-
ations in colony formation, followed by the standard
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay according to the manufacturer’s
instructions to evaluate the cell viability. Brieﬂy, 50 L/well
(in a 96-well sterile ﬂat-bottom microplate) of the Base
Agar Matrix Layer was prepared by mixing 1.25 mL
of 2× DMEM/20% FBS medium, 1 mL  of sterile water,
0.25 mL  of melted 10× CytoSelectTM Agar Matrix Solu-
tion. Cell Suspension/Agar Matrix Layer under sterile
conditions (75 L/well) was made by mixing 1.75 mL  of
2× DMEM/20% FBS medium, 1.375 mL  of CytoSelectTM
Matrix Diluent, 0.375 mL  of melted 10× CytoSelectTM
Agar Matrix Solution and 0.25 mL  of Cell Suspension.
Literally 103 and 105 cells of Huh-7 and Hep-3B were
added in the upper agar and incubated for 8 and 9 days,
respectively.
2.5. Immunoblotting analysis
Cell lysates were prepared with RadioImmunoPre-
cipitation Assay Buffer (#9806, Cell Signaling). Lysates
containing equal amounts of protein were separated
by 8, 10, 12 or 15% SDS-polyacrylamide gel elec-
trophoresis as appropriate and electroblotted onto the
polyvinylidene ﬂuoride membrane (ImmobilonTM Trans-
fer Membrane; Millipore). The ﬁlters were individually
probed with the primary anti-human antibodies, includ-
ing anti-human  actin (ACTB; 1:3000, #MAB1501,
Millipore), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; 1:1000, #ab128915, Abcam), cyclin-dependent
kinase 2 associated protein 1 (CDK2AP1, i.e., p12; 1:500
[54]), cyclin-dependent kinase inhibitor 2B (CDKN2B,
p15Ink4b; 1:500, sc-612, Santa Cruz), CDKN2C (p18Ink4c;
1:500, sc-865, Santa Cruz), CDKN2D (p19Ink4d; 1:500, sc-
1063, Santa Cruz), CDKN1A (p21Cip1; 1:1000, #2947, Cell
Signaling), CDKN1B (p27Kip1; 1:500, #3686, Cell Signaling),
CDKN1C (p57Kip2; 1:500, sc-1040, Santa Cruz), CDC28 pro-
tein kinase regulatory subunit 1B (CKS1B; 1:200, #36-6800,
Invitrogen), cyclin E1 (CCNE1; 1:500, sc-198, Santa Cruz),
cyclin-dependent kinase 2 (CDK2; 1:500, sc-163, Santa
Cruz), CCND1 (1:1000, #2926, Cell Signaling), CDK4 (1:500,
sc-260, Santa Cruz), CDK6 (1:500, sc-177, Santa Cruz),
RB1 (1:500, sc-102, Santa Cruz), E2F transcription factor 1
(E2F1; 1:500, sc-251, Santa Cruz), transcription factor Dp-1
(TFDP1; 1:500, sc-53642, Santa Cruz), S-phase kinase asso-
ciated protein 2, E3 ubiquitin protein ligase (SKP2; 1:500,
#32-3300, Invitrogen), poly(ADP-ribose) polymerase 1
(PARP1; 1:1000, #9542, Cell Signaling), APC/CFizzy/cell
division  cycle 20 related 1 (FZR1) (FZR1 E3 ligase, also known
as CDH1; 1:1000, GTX-111200, Genetex), acetyl-histone
H3 (1:10,000, #06-599, Merck Millipore), acetyl-histone
H4 (#06-866, Merck Millipore) and histone H3 contain-
ing the acetylated lysine 9 and 14 (H3K9/14ac; 1:10,000,
GTX-122648, Genetex) antibodies. Protein bands were
detected by Western LightningTM Chemiluminescence
reagent Plus ECL Kit (PerkinElmer), with horseradish-
peroxidase-labeled secondary antibodies as suggested
by the manufacturer and visualized on a VersaDocTM
Imaging System (Bio-Rad Life Science). The intensity of
bands from immunoblotting assays was quantiﬁed byorts 2 (2015) 322–332
densitometry and normalized to that of ACTB or GAPDH
in each lane.
2.6. Quantitative reverse transcription-polymerase chain
reaction
Total RNAs were extracted with TRIzol® isolation
reagent (Life Technologies) from cells followed by DNase
treatment and reverse transcription to synthesize cDNA
with Moloney Murine Leukemia Virus Reverse Trans-
criptase (Promega). TaqMan® chemistry with primers
and probes (Life Technologies): CDKN1B (#4331182;
151 bp, Hs01597588 m1,  NM 004064.3), CDKN1C
(#4331182; 91 bp, Hs00175938 m1,  NM 000076.2,
NM 001122630.1, NM 001122631.1), SKP2 (#4331182;
59 bp, Hs01021864 m1,  NM 001243120.1, NM 005983.3,
NM 032637.3) and GAPDH (#4453320; 93 bp,
Hs02758991 g1, NM 001256799.1, NM 002046.4) were
used for quantitative RT-PCR. The relative expression
folds of each target transcript were given by 2−CT,
where CT = CT (treatment) – CT (DMSO); CT
represented the CT of a target transcript subtracted
from the CT of GAPDH (internal control). Only samples
with CT value < 25 for GAPDH were considered to meet
acceptable RNA quality standards and included in the
analyses.
2.7. CHX-chase assay
A standard CHX-chase assay was  used to evaluate
whether CHX-inhibited CDKN1B protein synthesis could be
restored by GTN treatments. Brieﬂy, Huh-7 cells (3 × 105)
were grown in 6-well plates and treated with DMSO (con-
trol) and GTN (10 M)  for 24 h, respectively. Afterward,
CHX (25 g/mL) was added and cells were harvested at 0,
2, 4, 8 h and subjected to immunoblotting analysis.
2.8. Nuclear/cytosol fractionation
To examine changes of nuclear SKP2, CDK2 and CDKN1B
protein levels after GTN treatments, nuclear/cytosol frac-
tionation along with immunoblotting were performed. A
total of 106 Huh-7 cells were seeded in 10-cm tissue cul-
ture dishes and treated with DMSO (control) or GTN for
16 and 24 h, respectively. Nuclear/Cytosol Fractionation Kit
(K266-25, BioVision Inc.) was used to isolate nucleus and
cytosol using trypsinized cells according to the manufac-
turer’s instructions.
2.9. Histone extraction
The EpiSeeker Histone Kit (#ab113475, Abcam) was
used to isolate the histone protein. Brieﬂy, 106 of Hep-
3B cells were plated in 10-cm culture dishes. After TSA or
GTN treatments, trypsinized cells were resuspended with
1×, 100 L Pre-lysis Buffer in microtubes and incubated
on ice for 10 min. Cells were centrifuged at 9000 × g, 4 ◦C
for 1 min, and the supernatant was removed. The cells
were next resuspended in 20 L of Lysis Buffer and incu-
bated on ice for 30 min. Cells were centrifuged again at
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3,000 × g, 4 ◦C for 5 min  and the supernatant was  trans-
erred into new microtubes. Literally 60 L of Balance-DTT
uffer was added to balance the pH value and pro-
ein concentrations were determined for immunoblotting
nalysis.
.10. Statistics
Student’s t-test was used to examine the signiﬁcant
ifference between the averages of the control and the
xperimental group.
. Results
.1. GTN induced G0/G1 cell cycle arrest and inhibited
nchorage-independent cell growth in HCC-derived cells
ia upregulation of CDKN1B and CDKN1C expression
Half maximal inhibitory concentrations (IC50) of GTN
n Huh-7 and Hep-3B cells were determined as 20 and
5 M,  respectively (at 48 h) by the MTT  assay. To ana-
yze GTN-induced cell cycle arrest at the earliest, these
oncentrations were used for subsequent experiments.
low cytometric analysis showed that GTN treatments
or 24 h induced G0/G1 cell cycle arrest (P < 0.01) and
ecreased cell numbers in the S phase (P < 0.001) in
oth Huh-7 and Hep-3B cell lines (Fig. 1A and E).
oft agar assays further demonstrated that GTN treat-
ents suppressed colony formation (Fig. 1B and F) and
nchorage-independent cell growth (P < 0.001) in both the
ell lines (Fig. 1C and G). Accordingly, the protein lev-
ls of a series of CKIs, which control G1 to S progression
ncluding CDK2AP1, CDKN2B, CDKN2C, CDKN2D, CDKN1A,
DKN1B and CDKN1C were investigated. Immunoblot-
ing showed GTN-mediated upregulation of CDKN1B and
DKN1C protein levels in Huh-7 and Hep-3B cells, respec-
ively, among the seven CKIs examined (Fig. 1D and H).
herefore, GTN induces G0/G1 cell cycle arrest inhibits
nchorage-independent cell growth in HCC-derived cells
ia upregulation of CDKN1B and CDKN1C protein levels.
ow GTN induced CDKN1B and CDKN1C were further stud-
ed.
.2. GTN upregulated CDKN1B and CDKN1C but
ownregulated regulators of G1 to S phase in distinct
CC-derived cells
Immunoblotting analysis and a time-course experi-
ent identiﬁed the optimal GTN induction periods as
6 h (P < 0.05) and 24 h (P < 0.05) for CDKN1B and CDKN1C
rotein levels in Huh-7 and Hep-3B cells, respectively
Fig. 2A and C). Several G1- and S-phase regulatory proteins,
pstream or downstream of CKIs, including CKS1B, CCNE1,
CND1, CDK2, CDK4, CDK6, RB1, E2F1, and/or TFDP1 were
ownregulated after GTN treatments for 24 h (Fig. 2B and
). Accordingly, GTN upregulates CDKN1B and CDKN1C
rotein levels, accompanying by downregulation of sev-
ral regulators involving in the transition between G1 to S
hase of the mitotic cell cycle in distinct HCC-derived cell
ines.orts 2 (2015) 322–332 325
3.3. GTN stabilized nuclear CDKN1B protein via
degradation of its E3 ligase, SKP2 protein level in Huh-7
cells
In Huh-7 cells, GTN treatments for 24 h notably upre-
gulated CDKN1B but downregulated its E3 ligase, SKP2
protein level (Fig. 3A). In contrast, CDKN1B and SKP2
mRNA levels were not altered after GTN treatments in
time-course experiments (P > 0.05; Fig. 3B), signifying that
GTN increased SKP2 protein stability. Moreover, GTN aug-
mented and stabilized CHX-suppressed SKP2 and CDKN1B
protein levels, respectively, implying that GTN might be an
SKP2 inhibitor (Fig. 3A). A proteasome inhibitor, MG132,
stabilized the endogenous SKP2 and reversed the GTN-
inhibited SKP2 protein expression (Fig. 3C), suggesting that
SKP2 levels might also be regulated by the UPS pathway
in this cellular context. However, while GTN suppressed
SKP2 protein level, it did not regulate the coactivator
of the anaphase-promoting complex, FZR1, which targets
SKP2 for degradation in the G1 phase (Fig. 3D). Together
with immunoblotting analysis, cytosol/nuclear fraction-
ation demonstrated that nuclear CDKN1B protein level
was upregulated (P < 0.05) whereas SKP2 (P < 0.01) and
CDK2 (P < 0.01) levels were downregulated following GTN
treatments, indicating that GTN induces nuclear CDKN1B
expression by suppression of SKP2, and subsequently,
downregulates CDK2 protein levels (Fig. 3E). Thus, GTN
induces the CDKN1B protein level in Huh-7 cells by tar-
geting CDKN1B-speciﬁc E3 ligase, SKP2, for degradation.
3.4. GTN-induced CDKN1C mRNA levels via epigenetic
modiﬁcations in Hep-3B cells
In Hep-3B cells, a time-course experiment showed that
GTN treatments did not markedly alter SKP2 protein level
(P > 0.05; Fig. 4A) but upregulated CDKN1C mRNA level
(P < 0.01; Fig. 4B), indicating that GTN enhances CDKN1C
transcription. As shown in Fig. 4C, TSA rather than 5-Aza-dC
treatments, upregulated CDKN1C mRNA level (P < 0.001),
further demonstrating that inhibition of HDAC upregu-
lates CDKN1C mRNA level in Hep-3B cells. In addition,
compared to treatment with TSA or GTN alone, combined
treatment with GTN and TSA upregulated CDKN1C mRNA
levels (P < 0.001). On the other hand, cotreatment with
TSA, GTN, and 5-Aza-dC did not further upregulate CDKN1C
mRNA level as compared to cotreatment with TSA and GTN
(P > 0.05). However, the mRNA levels of CDKN1C induced
by the cotreatment of GTN and TSA were not immediately
reﬂected in their protein levels (Fig. 4D).
To further compare the roles between GTN- and TSA-
induced CDKN1C mRNA, a TSA-speciﬁc inhibitor, ITSA1
was used. Treatment with ITSA1 alone suppressed endoge-
nous CDKN1C mRNA level (P < 0.01), indicating that the
low CDKN1C mRNA level in Hep-3B cells was  inhibited
by the endogenous HDAC. Interestingly, GTN restored
the ITSA1-suppressed CDKN1C mRNA to the original level
(Fig. 4E); this effect was  however delayed at the pro-
tein level (Fig. 4F). Furthermore, immunoblotting analysis
showed that GTN upregulated global acetyl-histone H3 but
not acetyl-H4; this ﬁnding was  similar to that observed
in the TSA-treated group (Fig. 4G). A slight but distinct
326
 
Y.-T.
 Peng
 et
 al.
 /
 Toxicology
 R
eports
 2
 (2015)
 322–332
Fig. 1. Goniothalamin (GTN) induced cell cycle arrest and suppressed anchorage-independent cell growth via upregulation of cyclin-dependent kinase inhibitor 1B (CDKN1B) and CDKN1C protein levels in
HCC-derived cells. Flow cytometric assays demonstrated that treatment with GTN in TP53-mutated Huh-7 (20 M) and TP53-negative Hep-3B (15 M)  cells for 24 h induced G0/G1 and/or G2/M cell cycle
arrest; suppressed S-phase and increased sub-G1 apoptotic cells. Soft agar assays were performed for 7 d and 9 d in TP53-mutated Huh-7 and TP53-negative Hep-3B cells, respectively. Compared to DMSO
control  GTN-induced the inhibition of anchorage-independent cell growth (B, F). MTT assay further identiﬁed viable cells were decreased after GTN treatments in both cell lines (C, G). Screening on a series of
cyclin-dependent kinase inhibitors (CKIs) by immunoblotting analyses identiﬁed that CDKN1B and CDKN1C were notably upregulated in Huh-7 and Hep-3B cells, respectively, after treatments with GTN for 24 h,
while  the expression levels of other CKIs were downregulated or unchanged. All experiments were triplicated and representative immunoblotting images are shown. Statistical signiﬁcance: *P < 0.05; **P < 0.01;
***P < 0.001.
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Fig. 2. While Goniothalamin (GTN) increased the protein abundance of CDKN1B and CDKN1C, positive regulator proteins of G1 to S phase were downreg-
ulated  in Huh-7 and Hep-3B cells. Immunoblotting analysis demonstrated that (A, C) CDKN1B and CDKN1C protein levels were signiﬁcantly upregulated
after  GTN treatments for 8, 16 and 24 h in Huh-7 cells; for 16 and 24 h in Hep-3B cells, respectively. (B, D) Of several CDKN1B and CKDN1C upstream and
downstream G and S regulators, GTN notably suppressed CKS1B, CCNE1, CDK2, RB1, E2F1 and TFDP1 protein levels in Huh-7; CDK2, CCND1, CDK6, CDK4,
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2F1  and TFDP1 protein abundance in Hep-3B cells.
pregulation of H3K9/14 acetylated protein was  found
fter TSA or GTN treatment (Fig. 4H). Consequently, GTN
nduces CDKN1C mRNA level by playing a similar role to
hat of TSA in Hep-3B cells. The underlying molecular
echanisms of GTN-upregulated CDKN1B and CDKN1C in
istinct HCC-derived cells are summarized in Fig. 5.
. Discussion
This study demonstrated that a small natural com-
ound, GTN, induced G0/G1 cell cycle arrest and inhibited
nchorage-independent cell growth by modulating two
otent CKIs, CDKN1B and CDKN1C, in HCC-derived cell
ines with distinct genetic backgrounds. Uncontrolled pro-
iferation is one of the main hallmarks of human cancers[46]. In many cancers, including HCC [33], hyperactivity
of CDKs is one of the mechanisms underlying the physi-
ological hyperproliferation. Therefore, inhibition of CDKs
has emerged as a potential therapy and upregulation of
endogenous CKIs has become an alternative strategy to
inhibit hyperproliferation. This study indicates GTN as a
potent CKI inducer.
We found that after treatments with GTN for 24 h in
Huh-7 (20 M)  and Hep-3B (15 M)  cells, only a few were
identiﬁed in sub-G1 (i.e., apoptosis) while most (60–70%)
cells were arrested in G0/G1 phase. Therefore, GTN inhibits
the G1/S transition point via upregulation of the protein
levels of two  CKIs, namely CDKN1B and CDKN1C. Mem-
bers of the Cip/Kip family of CKIs are well characterized
for their role as negative regulators of G1-phase cell cycle
328 Y.-T. Peng et al. / Toxicology Reports 2 (2015) 322–332
Fig. 3. In Huh-7 cells, goniothalamin stabilized nuclear CDKN1B via downregulation of its E3 ligase SKP2 level. (A) GTN treatment for 24 h upregu-
lated  CDKN1B while downregulated SKP2 protein level [DMSO 24 h/Cycloheximide (CHX) 0 h vs. GTN 24 h/CHX, 0 h]. CHX-chase (0, 2, 4, 8 h) along with
immunoblotting assays estimated that the half-life of CDKN1B and SKP2 proteins were approximately 6 h. Compared to the DMSO group, GTN treatments
prolonged the stabilities of high CDKN1B and low SKP2 protein levels. (B) GTN treatments did not alter CDKN1B and SKP2 mRNA levels in a time course
experiment, compared to their corresponding controls (DMSO). (C) MG132 (5 M)  increased SKP2 protein abundance and further restored GTN-inhibited
SKP2  protein level. DMSO (control), GTN and MG132 were added at time 0, 0 and 16 h, respectively; the total reaction time was 20 h. (D) GTN treatments
for  8, 16 and 24 h downregulated SKP2, nevertheless, did not alter FZR1 (an E3 ligase of SKP2) protein abundance. (E) Fractionation of nuclear and cyto-
solic  proteins and immunoblotting analysis indicated that GTN notably induced nuclear CDKN1B, however, downregulated nuclear SKP2, CCNE1, CDK2,
pCDKN1B(T187) protein levels. PARP1 and GAPDH were served as nuclear and cytosolic control, respectively. All experiments were triplicated and results
are  expressed as mean ± SEM. Representative immunoblotting images are shown. Statistical signiﬁcance: *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 4. In Hep-3B cells, goniothalamin induced CDKN1C mRNA and subsequent protein levels via upregulation of acetyl-H3 and H3K9/14ac levels.
Immunoblotting identiﬁed that SKP2 (an CDKN1C-speciﬁc E3 ligase) protein level was  almost unchanged after GTN treatments for 8, 16 and 24 h. (B)
Quantitative RT-PCR showed that GTN upregulated CDKN1C mRNA levels in a time-dependent manner. (C) Treatments with trichostatin A (TSA; 100 ng/mL)
and  GTN (15 M)  for 24 h but not 5-Aza-2′-deoxycytidine (5-Aza-dC; 10 M)  for 72 h, upregulated CDKN1C mRNA level, compared to the control group
(DMSO). Combined treatments of TSA and GTN further upregulated CDKN1C mRNA level, compared to either treatment with TSA or GTN alone. (D) CDKN1C
translation was  delayed to 28 h when combined treatments with TSA and GTN, compared to its transcription level at 24 h. (E, F) ITSA1 (50 M,  24 h), a TSA-
speciﬁc inhibitor, downregulated endogenous and GTN-induced CDKN1C mRNA and protein levels, compared to the controls (DMSO). Similarly, CDKN1C
translation was delayed to 28 h when combined treatments with GTN and ITSA1. ITSA1 further downregulated GTN-induced CDKN1C mRNA and protein
levels.  (G) Immunoblotting analysis demonstrated that TSA and GTN notably upregulated acetyl-H3 but not acetyl-H4 protein level, with an additive effect.
(H)  Histone extraction and immunoblotting analysis further demonstrated that both TSA and GTN increased H3K9/14-acetylated proteins in Hep-3B cells,
with  a slightly additive effect. All experiments were triplicated and results are expressed as mean ± SEM. For immunoblotting analysis, representative
images are shown. GAPDH, ACTB and H3 were served as loading controls. Statistical signiﬁcance: *P < 0.05; **P < 0.01; ***P < 0.001.
330 Y.-T. Peng et al. / Toxicology Reports 2 (2015) 322–332
dependFig. 5. Summary on the goniothalamin (GTN)-induced cyclin-
progression. Based on the sequence homology and speci-
ﬁcity of action, CKIs are divided into two distinct families:
INK4 and Cip/Kip [48]. Members of the INK4 family,
namely CDKN2B, CDKN2A, CDKN2C and, CDKN2D, specif-
ically inhibit the activity of CDK4 and CDK6, whereas
Cip/Kip members, i.e., CDKN1A, CDKN1B, and CDKN1C
inhibit a broader spectrum of cyclin-CDK complexes
[14,17,29,43,50]. Therefore, GTN notably induces Cip/Kip
members of CKIs targeting spacious cyclin-CDK complexes
rather than the INK4 family in distinct HCC-derived cells.
Among all the CKIs examined, CDKN1B and CDKN1C
protein levels were particularly low in Huh-7 and Hep-
3B cells, respectively; GTN-induced CDKN1B and CDKN1C
expressions strongly correlated with decrement of the
rate of cell cycle entry at G1/S transition, anchorage-
independent cell growth and colony formation. The cell
cycle is regulated primarily by the activity of CDKs and
protein degradation by the UPS. In the S phase, ubiquitin-
ation of nuclear CDKN1B is triggered by phosphorylation of
threonine 187 [pCDKN1B(T187)] through CDK2-cyclin E/A
complexes when the number of CDK2-CCNE/A complexes
exceeds that of the available CDKN1 [18,36,47]. Then,
nuclear pCDKN1B(T187) is recognized by the ubiquitin-
ligase SKP1-cullin 1 (CUL1)-ring-box1, E3 ubiquitin protein
ligase (RBX1)-F box protein (SCF) SKP2 E3 ligase, i.e.,
SCFSKP2, and targets pCDKN1B(T187) for proteasomal
degradation [5]. In this process, CKS1B has been identi-
ﬁed as an essential cofactor [49]. SCFSKP2 and another UPS,
anaphase-promoting complex/cyclosome (APC/C) FZR1 E3
ligase (also known as CDH1) control each other, with SKP2
being ubiquitinated by APC/CFZR1 in G1 cell cycle [12]. Inent kinase inhibitors (CKIs) in distinct HCC-derived cell lines.
agreement with this, we  demonstrated that GTN-stabilized
nuclear CDKN1B protein level in the Huh-7 cellular model
by targeting SKP2 degradation. On the other hand, MG132
treatment indicated that SKP2 itself was  subjected to UPS
regulation. However, the protein level of E3 ligase of SKP2,
FZR1 was unchanged following GTN treatments in time-
course experiments, suggesting that GTN-targeted SKP2
degradation might be mediated by another E3 ligase.
In the Hep-3B cellular model, both CDKN1C mRNA
and protein levels were upregulated by GTN. Although
SCFSKP2 was also reported to target CDKN1C by ubiquitin-
mediated degradation [24], GTN did not signiﬁcantly alter
the SKP2 protein levels in a time-course experiment. These
observations suggested that GTN enhanced CDKN1C tran-
scription and its subsequent translation, i.e., GTN-induces
CDKN1C transcription epigenetically [42]. Histone modiﬁ-
cations such as hyperacetylation of histone H3 and H4 are
known as active marks and are often associated with ongo-
ing transcription [51]. We  showed that treatments with
an HDAC inhibitor (HDACi) such as TSA rather than an
inhibitor of DNA methyltransferase such as 5-Aza-dC, sig-
niﬁcantly upregulated the CDKN1C mRNA levels in Hep-3B
cells. Besides, GTN and TSA induced CDKN1C transcription
synergistically. The TSA-speciﬁc inhibitor, ITSA1 downreg-
ulated the endogenous as well as GTN-induced CDKN1C
mRNA levels strongly advocating that GTN is an HDACi
that partially exhibits similar function as TSA. To our sur-
prise, when cotreatment with TSA and GTN, or GTN  and
ITSA1, CDKN1C mRNA levels did not immediately reﬂect
to their corresponding protein levels, i.e., delayed trans-
lation was  observed. In addition, GTN and TSA additively
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nduced global acetyl-histone H3 but not H4 levels. Impor-
antly, both TSA and GTN can induce co-occurrence of H3K9
nd H3K14 acetylation. These results strongly suggested
hat GTN acts as a histone H3-speciﬁc HDACi to activate
DKN1C transcription and its subsequent translation.
Intriguingly, GTN targeted the degradation of SKP2, an
ncoprotein in human hepatocellular carcinoma [7], in
uh-7 but not in Hep-3B cells. A potential explanation for
his is the diverse genetic backgrounds between these cell
ines, since Hep-3B cell line lack TP53 and RB1 proteins. It
as been shown that GTN (50 M,  10 min) directly affected
itochondria leading to a hypoxia condition in coro-
ary artery smooth muscle cells [8]. In pulmonary artery
mooth muscle cellular model from Sprague-Dawley rats
nd pulmonary arteries in hypoxia-induced pulmonary
ypertension rats, hypoxia induces SKP2 mRNA and then
rotein levels [31]. Instead, hypoxia induces CDKN1B mRNA
xpression increases with hypoxia but does not prolong
DKN1B mRNA half-life in Rat1a ﬁbroblasts [13]. Accord-
ngly, there is no direct evidence that GTN-induced hypoxia
argeted SKP2 degradation. On the other hand, in human
roximal tubular epithelial HK-2 cells, CDKN1C mRNA was
pregulated at early time points of hypoxia, indicating
t is within the early wave of hypoxia-responsive gene
30]. Accumulating evidence has indicated that hypoxic
icroenvironment is one of the most important cellular
timuli in terms of the regulation of cellular epigenetic
tatus via histone modiﬁcation (review in [38]). Thus,
TN might upregulate CDKN1C mRNA by hypoxia-induced
pigenetic modiﬁcation, particularly in TP53- and RB1-
egative cells. Alternatively, GTN might potentially induce
pigenetic modiﬁcations in Huh-7 cells that indirectly trig-
er SKP2 degradation.
We  also demonstrated that GTN suppressed the protein
evels of several positive cell cycle regulators, including
KS1B, CCNE1, CCND1, CDK2, CDK4, CDK6, E2F1, and/or
FDP1, involved in G1/S transition of the cell cycle in
uh-7 and Hep-3B cell lines. During the cell cycle pro-
ression, D-type cyclins are synthesized ﬁrst and form
omplexes with CDK4 or CDK6, which then move into the
ucleus in eukaryotes. These complexes actuate the acti-
ation of later-acting CDK-cyclin complexes in two ways.
irst, CDK4-cyclin D-mediated phosphorylation inactivates
he RB family proteins, allowing the E2F-mediated tran-
cription of the genes encoding E-, A-, and B-type cyclins.
ext, CDK4-CCND1 sequesters inhibitory proteins such as
DKN1B and CDKN1C that would otherwise impede the
ctivity of E-, and A-type cyclin-bound CDKs (reviewed
n [35]). Consistent with these ﬁndings, GTN upregulates
he protein levels of CDKN1B and CDKN1C; downregulates
CKD1, CCNE1, and other positive cell cycle regulators.
Thus, we discovered that GTN is able to upregulate the
rotein levels of two critical CKIs, CDKN1B and CDKN1C
n distinct HCC-derived cells. In TP53-mutated and RB1-
ositive Huh-7 cells, GTN targets the E3 ligase SKP2
egradation and stabilizes CDKN1B protein level. On the
ther hand, in TP53- and RB1-negative Hep-3B cells, GTN
cts as an HDACi, triggers global acetylation on histone H3,
ncluding H3K9/14, thereby inducing CDKN1C transcription
nd its subsequent translation. Our ﬁndings provide novel
ndications for HCC management.
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